Vaccine Uptake in Italy, through the OBVIOUS Project and Other Independent Research
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Epidemiology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 7762
Special Issue Editors
Interests: medical statistics; epidemiology; outcomes research; public health
Interests: public health; vaccines; prevention; infectious diseases; one health; vaccine hesitancy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We welcome you to contribute to our Special Issue dedicated to vaccine uptake in Italy. This research area is of significant importance in the context of public health, especially in light of global challenges such as the COVID-19 pandemic.
Understanding and enhancing vaccine uptake is vital for achieving herd immunity, preventing disease outbreaks, and safeguarding the health of communities. With these goals in mind, the OBVIOUS Project (Observatory on Vaccine Hesitancy in Italy—Online UniBo Surveys) was launched in 2022 and will continue its activity in 2023, providing significant insights into vaccine uptake in Italy.
This Special Issue aims to explore the factors influencing vaccine uptake in Italy and to offer strategies to enhance vaccination rates. Our goal is to compile a comprehensive collection of rigorous, peer-reviewed evidence regarding vaccination rates and strategies to improve them.
We welcome both original research articles and reviews that explore various aspects of vaccine uptake in Italy. Potential research areas include articles examining vaccine rates, vaccine uptake, and vaccine hesitancy.
We look forward to receiving your contributions.
Dr. Davide Gori
Dr. Jacopo Lenzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine uptake
- vaccine hesitancy
- vaccination rates
- Italy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.